Hey there!
Very few commercial drug companies focus on hearing disorders. Even fewer focus on tinnitus. Otonomy does both. In this episode of the Tinnitus Talk Podcast, we spoke with David Weber (PhD), President and CEO, and Alan Foster (PhD), Chief Scientific Officer.
They shared their views on what they see as the "renaissance" of hearing research and how there is currently more investor appetite to address hearing issues. We discussed why Otonomy is not only seeking solutions for different kinds of hearing loss, but also tinnitus specifically. The interview covers each of the company's drugs in-depth, from its mechanism of action to commercialization plans.
Listen on:
- Tinnitus Talk Podcast (incl. timestamps and transcript)
- SoundCloud
- Apple Podcasts
- Spotify
We welcome any discussion, but please keep the following in mind when commenting:
- Off-topic comments, i.e. not directly responding to the content of the podcast, will be removed. So please do listen before commenting!
- While we welcome constructive criticism on ideas or policies, we do not tolerate direct attacks on individuals.
This episode was produced by @Markku and @Hazel, with the support from the following volunteers: @FGG, @Andrea Rings, and @AfroSnowman. Do you want to volunteer as well? Let us know!
We thank our Patreon supporters for making this podcast possible.
Don't forget to:
Sharing Is Caring
Share the podcast on your social media and with your tinnitus friends!